title: Extracellular and intracellular mechanisms that mediate the metastatic activity of exogenous osteopontin.
abstract: BACKGROUND
  Osteopontin affects several steps of the metastatic cascade. Despite direct correlation with metastasis in experimental systems and in patient studies, the extracellular and intracellular basis for these observations remains unsolved. In this study, the authors used human melanoma and sarcoma cell lines to evaluate the effects of soluble osteopontin on metastasis.
  
  
  METHODS
  Exogenous osteopontin or negative controls, including a site-directed mutant osteopontin, were used in functional assays in vitro, ex vivo, and in vivo that were designed to test the extracellular and intracellular mechanisms involved in experimental metastasis.
  
  
  RESULTS
  In the extracellular environment, the results confirmed that soluble osteopontin is required for its prometastatic effects; this phenomenon is specific, arginine-glycine-aspartic acid (RGD)-dependent, and evident in experimental models of metastasis. In the intracellular environment, osteopontin initially induced rapid tyrosine 418 (Tyr-418) dephosphorylation of the cellular homolog of the Rous sarcoma virus (c-Src), with decreases in actin stress fibers and increased binding to the vascular endothelium. This heretofore undescribed Tyr dephosphorylation was followed by a tandem c-Src phosphorylation after tumor cell attachment to the metastatic site.
  
  
  CONCLUSIONS
  The results of this study revealed a complex molecular interaction as well as a dual role for osteopontin in metastasis that depends on whether tumor cells are in circulation or attached. Such context-dependent functional insights may contribute to antimetastasis strategies.
authors.affiliation: Department of Genitourinary Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA.
authors.forename: Jami
authors.initials: J
authors.lastname: Mandelin
authors.forename: Emme C K
authors.initials: EC
authors.lastname: Lin
authors.forename: Dana D
authors.initials: DD
authors.lastname: Hu
authors.forename: Susan K
authors.initials: SK
authors.lastname: Knowles
authors.forename: Kim-Anh
authors.initials: KA
authors.lastname: Do
authors.forename: Xuemei
authors.initials: X
authors.lastname: Wang
authors.forename: E Helene
authors.initials: EH
authors.lastname: Sage
authors.forename: Jeffrey W
authors.initials: JW
authors.lastname: Smith
authors.forename: Wadih
authors.initials: W
authors.lastname: Arap
authors.forename: Renata
authors.initials: R
authors.lastname: Pasqualini
mesh_terms: D000199:Actins / Q000378:metabolism; D000818:Animals; D002448:Cell Adhesion; D045744:Cell Line, Tumor; D004730:Endothelium, Vascular / Q000378:metabolism; D016391:Genes, src; D006801:Humans; D008545:Melanoma / Q000378:metabolism / Q000473:pathology*; D051379:Mice; D009154:Mutation; D009362:Neoplasm Metastasis / Q000503:physiopathology; D009842:Oligopeptides / Q000378:metabolism; D053495:Osteopontin / Q000378:metabolism / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D011994:Recombinant Proteins / Q000494:pharmacology; D012509:Sarcoma / Q000378:metabolism / Q000473:pathology*; D015398:Signal Transduction
chemical_list: D000199:Actins; D009842:Oligopeptides; D011994:Recombinant Proteins; D053495:Osteopontin; C047981:arginyl-glycyl-aspartic acid